AVEO Oncology (AVEO) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. REGN
2. CRWD
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. TFII
9. LYB
10. RXRX

Go back to AVEO Oncology (AVEO) Tops Q2 EPS by 5c

AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update

August 5, 2021 4:05 PM EDT

Total 2Q 2021 Revenue of $7.6 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $6.7 Million

Pivotal Phase 3 TiNivo-2 Trial of FOTIVDA in Combination with OPDIVO® (nivolumab) on Track to Initiate Enrollment in 3Q 2021

COVID-19 Related Manufacturing Supply Shortages to Push Potential Registrational Study Start for Ficlatuzumab to 2023

Company to Host Conference Call Today at 4:30 p.m. ET

BOSTON--(BUSINESS WIRE)-- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the... More